Search research articles
Contact Us
Filters
Showing results (161-170 of 175) with videos related to
Page
of 18
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver
|
November 28, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B
Ryu Sasaki, Shigeo Shimose, Issei Saeki, et al.
Cancer Science
|
August 24, 2024
A novel index combining fecal immunochemical test, DNA test, and age improves detection of advanced colorectal adenoma
Yukari Inoue, Akiyo Ishiguro, Yutaka Suehiro, et al.
Oncology Letters
|
July 9, 2024
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice
Shigeo Shimose, Issei Saeki, Tetsu Tomonari, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma
Takanori Ito, Shigeo Shimose, Joji Tani, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
November 18, 2025
Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma
Issei Saeki, Yutaka Suehiro, Yurika Yamauchi, et al.
Plos One
|
September 25, 2024
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy
Issei Saeki, Shigeo Shimose, Tetsu Tomonari, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 28, 2025
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
Tetsu Tomonari, Shigeo Shimose, Issei Saeki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 18, 2025
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
Yuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Journal of Gastroenterology
|
October 1, 2020
Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study
Yuki Tahata, Hayato Hikita, Satoshi Mochida, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
August 21, 2025
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study
Takeshi Hatanaka, Shigeo Shimose, Takanori Ito, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 175) with videos related to
Sort By:
Page
of 18
Liver International : Official Journal of the International Association for the Study of the Liver
|
November 28, 2025
Efficacy and Safety of Atezolizumab Plus Bevacizumab for Patients With Hepatocellular Carcinoma and Child-Pugh Class B
Ryu Sasaki, Shigeo Shimose, Issei Saeki, et al.
Cancer Science
|
August 24, 2024
A novel index combining fecal immunochemical test, DNA test, and age improves detection of advanced colorectal adenoma
Yukari Inoue, Akiyo Ishiguro, Yutaka Suehiro, et al.
Oncology Letters
|
July 9, 2024
Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice
Shigeo Shimose, Issei Saeki, Tetsu Tomonari, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 3, 2025
Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma
Takanori Ito, Shigeo Shimose, Joji Tani, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
November 18, 2025
Validation of Liquid Biopsy Using a Methylated SEPT9 Assay and Integrated Index for Detecting Hepatocellular Carcinoma
Issei Saeki, Yutaka Suehiro, Yurika Yamauchi, et al.
Plos One
|
September 25, 2024
Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy
Issei Saeki, Shigeo Shimose, Tetsu Tomonari, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
May 28, 2025
A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma
Tetsu Tomonari, Shigeo Shimose, Issei Saeki, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 18, 2025
Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
Yuta Myojin, Hayato Hikita, Yuki Tahata, et al.
Journal of Gastroenterology
|
October 1, 2020
Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study
Yuki Tahata, Hayato Hikita, Satoshi Mochida, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
August 21, 2025
Association of Metabolic-Associated Steatotic Liver Disease With Clinical Outcomes of Durvalumab and Tremelimumab in Advanced Hepatocellular Carcinoma Patients: A Multicenter Study
Takeshi Hatanaka, Shigeo Shimose, Takanori Ito, et al.
Page
of 18